- Home
- KZR
KZR
Kezar Life Sciences Inc.
as 04-18-2025 12:38pm EST
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | N/A | IPO Year: | 2018 |
| Target Price: | $9.00 | AVG Volume (30 days): | 34.0K |
| Analyst Decision: | Hold | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -11.49 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.62 - $9.20 | Next Earning Date: | 05-08-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Kezar Life Sciences Inc. News
KZR Breaking Stock News: Dive into KZR Ticker-Specific Updates for Smart Investing
Business Wire
25 days ago
Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results
Business Wire
a month ago
Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025
Business Wire
2 months ago
Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025
MT Newswires
2 months ago
Kezar Life Sciences Files $400 Million Mixed Securities Shelf
Clinical Trials Arena
5 months ago
Kezar struck again with second FDA hold
MT Newswires
6 months ago
Kezar Life Sciences to Implement 1-for-10 Reverse Stock Split
Business Wire
6 months ago
Kezar Life Sciences Announces 1-for-10 Reverse Stock Split
Clinical Trials Arena
6 months ago
Kezar Life Sciences discontinues lupus nephritis programme after fatalities
Compare KZR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KZR Kezar Life Sciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.